I am a biologist always excited to contribute to the discovery of new treatments. I received a BA in Biochemistry and Molecular Biology as well as a Master of Public Health from Boston University. I began my scientific career at Beth Israel Deaconess Medical Center developing antibodies for NHP models of disease. Following this role, I joined Editas Medicine, a CRISPR company, where I looked at Cas9 biology and contributed to the genotoxicity assessments for several IND-enabling programs. Prior to joining Entact Bio, I supported target validation efforts in the muscle and oncology programs at Faze Medicines, a biomolecular condensate start up.
See what Hayat and their colleagues have been up to:
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...
Entact Bio: Victoria Richon, CEO
The language of drug development is often militaristic. Medicinal chemists build arsenals of small molecules—looking for inhibitors or “warheads” that can hit “targets” and “combat” disease. Block, eliminate, disrupt, halt. For decades, drug makers have sought “magic bullets” that can precisely destroy ...
Entact Bio launches with $81 million to enhance protein function
When proteins within the body get tagged with a molecule called ubiquitin, they are essentially marked for destruction. But they can be saved; a deubiquitinase enzyme can remove the ubiquitin, keeping the protein intact. That, at least in part, is what Entact Bio aims to do...